Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2023 Sep;83(14):1315-1321. doi: 10.1007/s40265-023-01928-y.
Ritlecitinib (LITFULO), an orally administered kinase inhibitor, is being developed by Pfizer for the treatment of alopecia areata, vitiligo, ulcerative colitis and Crohn's disease. On 23 June 2023, ritlecitinib received approval in the USA for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Ritlecitinib was approved in Japan on 26 June 2023 for the treatment of alopecia areata (limited to intractable cases involving widespread hair loss). Ritlecitinib has also received a positive opinion in the EU and is under regulatory review in the UK and China. This article summarizes the milestones in the development of ritlecitinib leading to this first approval for severe alopecia areata.
利特昔替尼（LITFULO）是一种口服激酶抑制剂，由辉瑞公司开发，用于治疗斑秃、白癜风、溃疡性结肠炎和克罗恩病。2023 年 6 月 23 日，利特昔替尼获得美国批准，用于治疗成人和 12 岁及以上青少年的重度斑秃。2023 年 6 月 26 日，利特昔替尼在日本获批用于治疗斑秃（仅限于涉及广泛脱发的难治性病例）。利特昔替尼在欧盟也获得了积极意见，正在英国和中国接受监管审查。本文总结了利特昔替尼开发的里程碑事件，最终使其获得了重度斑秃的首次批准。
